Sukumar Nagendran, President and Head of R&D at Taysha Gene Therapies, Inc. (TSHA), sold 200,000 shares at $4.46 ($892K) on 2026-04-10, disclosed to the SEC on 2026-04-13.
Scheduled sale ($892k) by President and Head of R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| TSHA | SELL | 2026-01-14 | $942K | — | Filing → |
| TSHA | SELL | 2025-12-01 | $3.4M | — | Filing → |
| TSHA | SELL | 2025-09-12 | $646K | — | Filing → |